The adaptogen aisle can feel overwhelming when you're already exhausted and just want something to help. What nobody tells you is that most of these herbs have been tested on stressed college students or menopausal rats — not on women in their late forties dealing with hot flashes at 3am. Knowing that upfront changes how you shop.
Learn more about Rose →Ashwagandha sits at the top of this list because it has more rigorous human trial data than almost any other adaptogen studied in perimenopausal and menopausal women. A 2021 randomized controlled trial published in the Journal of Obstetrics and Gynaecology Research found that 300mg of root extract twice daily significantly reduced hot flash frequency, sleep disturbance, and anxiety scores compared to placebo over eight weeks. Its mechanism is thought to involve modulation of the hypothalamic-pituitary-adrenal (HPA) axis and partial GABAergic activity, which may explain benefits for both stress response and sleep architecture.
Rhodiola has good RCT evidence for reducing fatigue, burnout, and mild depressive symptoms in adults under chronic stress — conditions that overlap heavily with perimenopause. Its active compounds, rosavins and salidroside, appear to regulate serotonin and dopamine reuptake, which could support the mood disruptions that often accompany estrogen fluctuation. However, very few trials have recruited specifically menopausal women, so extrapolating from the general stress literature requires a degree of caution.
Schisandra has been used in Traditional Chinese Medicine for menopausal symptoms for centuries, and it has begun to accumulate modern trial data to support some of those uses. A small but well-designed RCT found reductions in hot flash frequency and night sweats in postmenopausal women taking a standardized schisandra extract compared to placebo. The proposed mechanism involves weak phytoestrogenic activity alongside adaptogenic effects on cortisol regulation, though the trial sizes are still too small to assign high confidence.
American ginseng has been studied more directly in menopausal women than Panax ginseng, including a notable trial at the Mayo Clinic that found modest reductions in hot flash severity compared to placebo. Its ginsenosides appear to exert mild adaptogenic effects on the HPA axis without the more stimulating properties sometimes reported with Asian ginseng, making it a more tolerable option for women already dealing with anxiety or sleep disruption. The evidence is encouraging but still limited to a handful of trials, none of them large-scale.
Maca has accumulated a reasonable body of small RCT evidence suggesting it reduces self-reported anxiety, depression, and sexual dysfunction in postmenopausal women — without measurably altering estrogen or FSH levels, which makes it genuinely interesting. Its mechanism remains unclear; researchers have proposed that it may work through glucosinolate compounds acting on hypothalamic signalling rather than via estrogenic pathways, which is relevant for women who need to avoid phytoestrogens. The evidence quality is moderate, limited by small sample sizes and variable preparations across studies.
Panax ginseng has decades of research behind it, but its direct application to menopausal symptoms is less clearly established than its general adaptogenic effects on cognitive function and physical fatigue. Some trials have shown improvements in quality of life scores in menopausal women, though effects on vasomotor symptoms like hot flashes are inconsistent across studies. Women with anxiety, hypertension, or insomnia are often advised to use it with caution, as its stimulating properties can exacerbate those symptoms at higher doses.
Holy basil has credible human trial data showing reductions in cortisol, perceived stress, and anxiety — outcomes that matter enormously during perimenopause when the adrenal system is under additional demand as ovarian hormone production declines. The problem is that no well-designed trials have recruited menopausal women specifically, so the case for tulsi rests on mechanistic plausibility rather than direct evidence. It is a reasonable low-risk option for stress support, but women should be clear-eyed that they are extrapolating from a related but not identical population.
Eleuthero was once one of the most studied adaptogens in Soviet-era sports medicine research, but much of that early work has not been replicated to modern trial standards, making it difficult to know what to trust. There is some preliminary evidence for reduced fatigue and improved stress resilience, which overlaps with perimenopause complaints, but no RCTs specifically in menopausal populations have produced clear positive findings. It sits lower on this list not because it is likely harmful, but because the evidence base simply has not kept pace with its longstanding marketing presence.
Shatavari is deeply embedded in Ayurvedic practice as a tonic for female reproductive health across the lifespan, and it contains steroidal saponins that are thought to exert mild phytoestrogenic effects. However, rigorous RCT data in menopausal women is almost entirely absent from the Western scientific literature, with most evidence coming from animal studies or small uncontrolled human trials. Women considering shatavari should weigh the long traditional use record against the genuine absence of modern trial verification — and flag its phytoestrogenic properties with any clinician managing hormone-sensitive conditions.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.